180 related articles for article (PubMed ID: 25367716)
1. Dulaglutide: first global approval.
Sanford M
Drugs; 2014 Nov; 74(17):2097-103. PubMed ID: 25367716
[TBL] [Abstract][Full Text] [Related]
2. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
[TBL] [Abstract][Full Text] [Related]
3. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.
Jimenez-Solem E; Rasmussen MH; Christensen M; Knop FK
Curr Opin Mol Ther; 2010 Dec; 12(6):790-7. PubMed ID: 21154170
[TBL] [Abstract][Full Text] [Related]
4. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
5. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
6. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217
[TBL] [Abstract][Full Text] [Related]
7. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
Lancet; 2019 Jul; 394(10193):121-130. PubMed ID: 31189511
[TBL] [Abstract][Full Text] [Related]
8. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
9. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez LE; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
Lancet Neurol; 2020 Jul; 19(7):582-590. PubMed ID: 32562683
[TBL] [Abstract][Full Text] [Related]
10. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
Lancet; 2019 Jul; 394(10193):131-138. PubMed ID: 31189509
[TBL] [Abstract][Full Text] [Related]
11. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
Lancet Diabetes Endocrinol; 2020 Feb; 8(2):106-114. PubMed ID: 31924562
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
13. Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
Pace E; Tingen J
Am Fam Physician; 2017 Oct; 96(8):540-542. PubMed ID: 29094890
[No Abstract] [Full Text] [Related]
14. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
15. Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.
Moreno Obregón F; Miramontes-González JP; Romo Guajardo-Fajardo C; Nieto-Sánchez Á; López-Suárez JM; Martín-Vallejo J; Arco-Prados Y; Dolores García de Lucas M; León-Jiménez D
Diabetes Res Clin Pract; 2019 Dec; 158():107916. PubMed ID: 31682882
[TBL] [Abstract][Full Text] [Related]
16. An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks.
Usborne A; Byrd RA; Meehan J; Blackbourne JL; Sullivan J; Poitout-Belissent F; Prefontaine A; Martin JA; Vahle JL
Toxicol Pathol; 2015 Dec; 43(8):1093-102. PubMed ID: 26269615
[TBL] [Abstract][Full Text] [Related]
17. Two new doses of dulaglutide (Trulicity) for diabetes.
Med Lett Drugs Ther; 2020 Oct; 62(1609):168. PubMed ID: 33429412
[No Abstract] [Full Text] [Related]
18. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
[TBL] [Abstract][Full Text] [Related]
20. Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
Garg A; Kumar A
Curr Drug Saf; 2018; 13(3):165-170. PubMed ID: 29852875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]